Avantium provides Crystal 16TM to all research sites of Sanofi-Aventis

Avantium Technologies has announced an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16™ at all R&D centres of Sanofi-Aventis.

Sanofi-Aventis has selected the Crystal16™:
- for the enhancement of its crystallisation research capabilities
- to increase the experimental throughput of its scientists
- to perform crystallisation experiments on a smaller scale

The Crystal16™ is a novel and proprietary platform that can be used for a range of applications in pharmaceutical and chemical research.

Users of the Crystal16™ are capable of running 16 experiments in parallel retrieving maximum knowledge about the crystallisation process and solid-state of their product.

Avantium International B.V.

Avantium International B.V.
R&D services

Downloads

DownloadFull Press Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.